November 18, 2020 11:06 AM ESTUpdated 11:20 AM
R&D

Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

Jason Mast

Editor

Pan­dem­ic aside, the last cou­ple years at Gilead have been all about ex­pan­sions: Mov­ing be­yond the HIV and he­pati­tis C an­tivi­rals that made them in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times